Clinical Management of Argatroban in Patients With Heparin Induced Thrombocytopenia Type II
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to collect data on the clinical management of Argatroban in
patients with suspected or confirmed heparin-induced thrombocytopenia Type II, with or
without ongoing thrombosis who require parenteral antithrombotic therapy